Mimetas

MIMETAS (Leiden, the Netherlands, Gaithersburg, USA, Tokyo, Japan) provides organ-on-a-chip products for compound testing, screening, and fundamental research. Its flagship product, the OrganoPlate®, supports 3D cell culture under continuous perfusion, with membrane-free co-culture and epithelial and endothelial tubules. The company develops and validates customized disease, toxicology, and transport models and ultimately will make its technology available for personalized therapy selection. MIMETAS has developed models for the kidney, liver, gut, brain, and a range of oncological applications, that offer better predictivity towards human physiology as compared to laboratory animals and conventional cell culture models. MIMETAS works with the majority of the global top-50 pharmaceutical companies, in addition to chemical, food, and consumer goods companies. The fast market acceptance of the OrganoPlate® is driven by its unsurpassed ease-of-use and throughput, in combination with complex human biology and disease relevance.